N1VO34:BVMF
Novo Nordisk Bdr
R$24,00
0,00%
(0,00) 1D
9 ຕ.ລ., 17 ໂມງ 5 ນາທີ 00 ວິນາທີ GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for N1VO34...
Open
R$24,20
High
R$24,20
Low
R$23,80
Mkt. cap
129,72 ຕື້
Avg. vol.
35,62 ພັນ
Volume
8,94 ພັນ
52-wk high
R$42,43
52-wk low
R$22,90
Shares outstanding
3,39 ຕື້
No. of employees
67 ພັນ
Open
R$24,20
High
R$24,20
Low
R$23,80
Mkt. cap
129,72 ຕື້
Avg. vol.
35,62 ພັນ
Volume
8,94 ພັນ
52-wk high
R$42,43
52-wk low
R$22,90
Shares outstanding
3,39 ຕື້
No. of employees
67 ພັນ
News stories
From web sources and news partners
Zacks Investment Research
·
4 ຊົ່ວໂມງກ່ອນ
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Investing.com India
·
5 ຊົ່ວໂມງກ່ອນ
BMO cuts Novo Nordisk stock price target on Ozempic headwinds By Investing.com
Foreign Policy Journal
·
5 ຊົ່ວໂມງກ່ອນ
Novo Nordisk (NYSE: NVO) Repurchases Over 23 Million B Shares Under DKK 15 Billion Buyback Programme
GlobeNewswire
·
9 ຊົ່ວໂມງກ່ອນ
Novo Nordisk A/S - share repurchase programme
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk Bdr
CEOMaziar Mike Doustdar
Employees66,7 ພັນ
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, ເດນມາກ
SectorPharmaceutical industry
Websitenovonordisk.com